The Rising Cost of Developing Cardiovascular Therapies and Reproducibility in Translational Research: Do Not Blame It (All) on the BenchOpen Access

References

• 1. van Norman G. "Overcoming the declining trends in innovation and investment in cardiovascular therapeutics: beyond EROOM’s Law". J Am Coll Cardiol Basic Trans Science 2017;2:613-625.

  View ArticleGoogle Scholar

• 2. Scannell J.W., Blanckley A., Boldon H., Warrington B. "Diagnosing the decline in pharmaceutical R&D efficiency". Nat Rev Drug Discov 2012;11:191-200.

  CrossrefMedlineGoogle Scholar

• 3. Begley C.G., Ioannidis J.P. "Reproducibility in science: improving the standard for basic and preclinical research". Circ Res 2015;116:116-126.

  CrossrefMedlineGoogle Scholar

• 4. Ioannidis J.P. "Acknowledging and overcoming nonreproducibility in basic and preclinical research". JAMA 2017;317:1019-1020.

  CrossrefMedlineGoogle Scholar

• 5. Ledford H. "Translational research: 4 ways to fix the clinical trial". Nature 2011;477:526-528.

  CrossrefMedlineGoogle Scholar

• 6. Perel P., Roberts I., Sena E., et al. "Comparison of treatment effects between animal experiments and clinical trials: systematic review". BMJ 2007;334:197.

  CrossrefMedlineGoogle Scholar

• 7. Tufts Center for the Study of Drug Development. "Causes of clinical failures vary widely by therapeutic class, phase of study. Tufts CSDD study assessed compounds entering clinical testing in 2000–09". Tufts CSDD Impact Report 2013;15:5.

  Google Scholar

• 8. Hwang T.J., Lauffenburger J.C., Frankin J.M., Kesselheim A.S. "Temporal trends and factors associated with cardiovascular drug development, 1990 to 2012". J Am Coll Cardiol Basic Trans Science 2016;2:301-308.

  Google Scholar

• 9. Grignolo A., Pretorius S. "Phase III trial failures: costly, but preventable". Applied Clinical Trials 2016;25 [serial online] . Available at: http://www.appliedclinicaltrialsonline.com/print/318912?page=full&pageID=3. Accessed September 24, 2017.

  Google Scholar

• 10. Pfeffer M.A., Claggett B., Assmann S.F., et al. "Regional variation in patients and outcomes in the Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist (TOPCAT) trial". Circulation 2015;131:34-42.

  CrossrefMedlineGoogle Scholar

• 11. Bristow M.R., Enciso J.S., Gersh B.J., et al. "Detection and management of geographic disparities in the TOPCAT trial: lessons learned and derivative recommendations". J Am Coll Cardiol Basic Trans Science 2016;1:180-189.

  View ArticleGoogle Scholar

• 12. Mann D.L., Annex B.H., Bishopric N.H., et al. "Introducing JACC: Basic to Translational Science: Why now?"J Am Coll Cardiol Basic Trans Science 2016;1:1-2.

  View ArticleGoogle Scholar